The Frequency of CYP2C19*2 Gene Polymorphisms in Burkina Faso Patients Treated with Clopidogrel
This study provides valuable insights into the frequency of the CYP2C19*2 polymorphism among cardiovascular patients in Burkina Faso, contributing to the limited data available on <i>CYP2C19</i> polymorphisms in sub-Saharan Africa. The presence of loss-of-function alleles suggests a potential risk for reduced drug efficacy in a subset of individuals. As one of the pioneering studies in the region, these findings emphasize the importance of further research to understand the clinical implications of <i>CYP2C19</i> polymorphisms.
Authors
- Abdoul Karim Ouattara (ORCID: https://orcid.org/0000-0002-9767-0646)
- Teega‐Wendé Clarisse Ouedraogo (ORCID: https://orcid.org/0000-0002-3121-8761)
- Jacques Simporè (ORCID: https://orcid.org/0000-0002-0415-9161)
- Lassina Traoré (ORCID: https://orcid.org/0000-0003-4719-380X)
- Nobila Valentin Yaméogo (ORCID: https://orcid.org/0000-0003-2791-7882)
- Yves Donald Kagambèga
Institutions
- Université Joseph Ki-Zerbo (BF)
- Centre Hospitalier Universitaire Yalgado Ouédraogo (BF)
- University of Koudougou (BF)
Publication Details
- Journal
- The Application of Clinical Genetics
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/tacg.s509095
- Citations
- 1
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.39